Skip to content

Immediate analgesic effects of cheek acupuncture for acute gouty arthritis: protocol for a randomised controlled trial

Immediate analgesic effects of cheek acupuncture for acute gouty arthritis: protocol for a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005411
Enrollment
Unknown
Registered
2021-12-17
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute gouty arthritis

Interventions

Etoricoxib group:Etoricoxib 120mg for oral use
TW group:cheek acupuncture

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Meet the diagnostic criteria for acute gouty arthritis and with attacks in the unilateral ankle or first metatarsophalangeal joint; ? Age =18 years old and =75 years old, regardless of gender; ? The gouty arthritis attack is within 48h; ? Without therapy with targeted topical treatment or self-administered medications including colchicine, anti-inflammatory pain medications, hormones, herbs, etc. Agreement to comply with the clinician's treatment plan.

Exclusion criteria

Exclusion criteria: ? Pregnant or breast-feeding ? Patients with malignant tumors, severe dysfunction of the heart, liver, and kidneys, diabetes mellitus and hypertension ? Mental disorders that render the patient unable to understand the nature of the study, its scope, and possible outcomes or unable to follow the doctor's advice ? Allergic to the components of the drug in this study ? Patients with active peptic ulcers/bleeding, or previous recurrent ulcers/bleeding. ? History of asthma, urticaria or allergic reactions induced by taking aspirin or other non-steroidal anti-inflammatory drugs ? Congestive heart failure (New York Heart Association [NYHA] cardiac function class II-IV)

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scoring;Patient feedback on this treatment;mobility impairment;joint tenderness;Immediate pain relief;

Countries

China

Contacts

Public ContactLin Yuping
396277116@qq.com13570459624

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026